Dr. Denise A. Valenti
Dr. Valenti is the owner and chief operating officer of IMMAD. The company provides education, services and technology for the responsible use of marijuana. Dr. Valenti is residency trained in vision and sensory rehabilitation and this included extensive clinical exposure to the legal and rehabilitation aspects related to medical impairment and driving. Dr. Valenti has decades direct clinical experience related to sensory impairment, including the integration of vision impairment services into the rehabilitation strategies of complex multisystem impairments such as stroke, traumatic brain injury and Parkinson’s disease. Dr. Valenti has held her own funding through NIH (supplement to study function and structure in Alzheimer’s disease), Forest Labs pharmaceutical (PI-The drug Namenda, study of structure and function related to drug efficacy in Alzheimer’s disease), Fight for Sight non-profit (PI-Parkinson’s disease retinal dopamine function and structure study) and Healthy 2010 (Author and Principal-Educating African Americans with the Objective of Reducing the Risk of Vision Loss Due to Alzheimer’s Disease, Diabetes and Glaucoma). Dr. Valenti was recognized by the Alzheimer’s Drug Discovery Foundation as their Outstanding Young Researcher in 2006. Most recently Dr. Valenti wrote and worked on a Blue Hills Community Health Alliance development grant–Empowering Veterans Enabling Success. Dr. Valenti has been active in the science community related to cannabinoids with the emphasis on brain, sensory neuroprocessing and cognitive impact. She has presented both nationally and internationally.